For years, apremilast (brand name Otezla) has helped psoriasis patients achieve clearer skin and ease the symptoms of their psoriatic arthritis. Now, new data from researchers at the Perelman School of Medicine at the University of Pennsylvania shows it could also help people with psoriasis shed unhealthy body fat and therefore improve cardiovascular health, a well-known vulnerability for those with psoriasis. The findings are published in JAMA Dermatology.
"The study's most provocative findings are that the drug decreased subcutaneous and visceral fat," said first study author Joel M. Gelfand, MD, MSCE, vice chair of clinical research and medical director of the Penn Medicine Dermatology Clinical Studies Unit, director of the Psoriasis and Phototherapy Treatment Center, and the James J. Leyden, M.D. Endowed Professor in Clinical Investigation in the Department of Dermatology.